IPF is a devastating disease characterized by the development of pulmonary fibrosis which starts in the subpleural region. Myofibroblasts populate the lung parenchyma in patients with IPF. However, their origin remains unclear. The pleural mesothelium derived from the mesoderm lines the lung and expresses the Wilms tumor gene (Wtl). In recent studies we have demonstrated that pleural mesothelial cells can differentiate into myofibroblasts and that pleural mesothelial cells are found in the lung parenchyma of patients with IPF. We hypothesize that pleural mesothelial cells (PMCs) contribute to the myofibroblast population in animal models of fibrogenic lung injury and in human IPF. In collaboration with the other projects in this proposal we will examine our hypothesis in the following specific aims: 1. Determine if PMCs traffic into the lung to form myofibroblasts in animal models of fibrogenic lung injury. 2. Determine the spatial profusion of PMCs in the lung parenchyma of IPF patients in histopathological 3D reconstruction studies and correlate with severity and/or progression of lung fibrosis. 3. Determine the regulatory role of Wtl in the contractile, migratory and fibrogenic activities of normal and IPF-derived PMCs. 4. Determine if small molecule inhibitor, GKT137831 and/or miR-31 delivered via the intra-pleural route protects against fibrosis in murine models of fibrosis Using a cre-lox system for lineage tracing of PMCs, we will examine the role of PMCs in IPF and the contribution of Wtl in modulating migration and differentiation of myofibroblasts. Using human cells and tissue, we will determine the role of IPF-PMCs in the pathology of IPF. These studies will stimulate new paradigms in IPF and define the contribution of the pleural mesothelium to lung parenchymal fibrosis. Local intrapleural delivery of small molecules targeting novel pathways will advance our development of directed therapeutics against IPF.
These studies will simulate new concepts in IPF and define the contribution of the pleural mesothelium to lung parenchymal fibrosis. New paradigms including intrapleural delivery of therapeutic molecules targeting the pleural mesothelium will be evaluated.
|Pennathur, Subramaniam; Vivekanandan-Giri, Anuradha; Locy, Morgan L et al. (2016) Oxidative Modifications of Protein Tyrosyl Residues Are Increased in Plasma of Human Subjects with Interstitial Lung Disease. Am J Respir Crit Care Med 193:861-8|
|Liu, Rui-Ming; Eldridge, Stephanie; Watanabe, Nobuo et al. (2016) Therapeutic potential of an orally effective small molecule inhibitor of plasminogen activator inhibitor for asthma. Am J Physiol Lung Cell Mol Physiol 310:L328-36|
|Larson-Casey, Jennifer L; Deshane, Jessy S; Ryan, Alan J et al. (2016) Macrophage Akt1 Kinase-Mediated Mitophagy Modulates Apoptosis Resistance and Pulmonary Fibrosis. Immunity 44:582-96|
|Kurundkar, Ashish; Thannickal, Victor J (2016) Redox mechanisms in age-related lung fibrosis. Redox Biol 9:67-76|
|Kulkarni, Tejaswini; Willoughby, John; Acosta Lara, Maria Del Pilar et al. (2016) A bundled care approach to patients with idiopathic pulmonary fibrosis improves transplant-free survival. Respir Med 115:33-8|
|Rangarajan, Sunad; Kurundkar, Ashish; Kurundkar, Deepali et al. (2016) Novel Mechanisms for the Antifibrotic Action of Nintedanib. Am J Respir Cell Mol Biol 54:51-9|
|Rangarajan, Sunad; Locy, Morgan L; Luckhardt, Tracy R et al. (2016) Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now? Drugs 76:291-300|
|Kulkarni, Tejaswini; de Andrade, Joao; Zhou, Yong et al. (2016) Alveolar epithelial disintegrity in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 311:L185-91|
|Cui, Huachun; Banerjee, Sami; Xie, Na et al. (2016) MicroRNA-27a-3p Is a Negative Regulator of Lung Fibrosis by Targeting Myofibroblast Differentiation. Am J Respir Cell Mol Biol 54:843-52|
|Swamy, Shobha M; Rajasekaran, Namakkal S; Thannickal, Victor J (2016) Nuclear Factor-Erythroid-2-Related Factor 2 in Aging and Lung Fibrosis. Am J Pathol 186:1712-23|
Showing the most recent 10 out of 51 publications